The Global Dasatinib Drugs Market Size Was Valued at USD 1.36 Billion in 2023 and is Projected to Reach USD 2.5 Billion by 2032, Growing at a CAGR of 6.98% From 2024-2032. Dasatinib is a potent, second-generation tyrosine kinase inhibitor (TKI) primarily utilized in the treatment of specific types of blood cancers, most notably Philadelphia chromosome-positive ($Ph+$) Chronic Myeloid Leukemia...